Genalyte’s U.S. Food and Drug Administration (FDA)-cleared Maverick™ Diagnostic System will expand antibody testing in the fight against COVID-19 with the launch of its SARS-CoV-2 Multi-Antigen Serology Panel. The antibody test and results represent a crucial step in helping to develop an understanding of the virus, including how long antibodies stay in the body and if they are less susceptible to reinfection. Currently, Genalyte has the capacity to test 250,000 patients per month and the company is scaling to test over 7,500,000 patients per month by September.
READ MORE
